Loading
Life sciences · Journal article
Cancer Immunology Immunotherapy · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The field of immunometabolism has highlighted the importance of metabolic signals in regulating immune responses. Various classes of ion channels act as sensors of these metabolic signals, modulating ion influx (e.g., Ca2 +, Na +, K +) and downstream signalling pathways that influence immune cell activation and inflammatory responses. This review focuses on the role of N-methyl-D-aspartate (NMDA) ion channels in promoting an immunosuppressive tumour microenvironment in response to metabolic cues. These ligand-gated cation channels modulate myeloid cell signalling and metabolism, resulting in M2 macrophage polarisation and myeloid-derived suppressor cell (MDSC) activity. Recent studies indicate that combining the ion channel antagonists with anti-PD-1/PD-L1 therapy enhances immunotherapy efficacy, underscoring ion channel signalling as an attractive target to improve treatment outcomes.